Harrow Health Publishes Second Quarter 2020 Letter to Stockholders

NASHVILLE, Tenn., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today reported results for the second quarter 2020.  Please click here to review Harrow Health’s Letter to Stockholders for the second quarter 2020.

Mark L. Baum, CEO of Harrow Health, commented, “Our team made great progress during a challenging second quarter.  The impact from COVID-19 was substantial for a limited period, but the segments of our economy that are most relevant to our success recovered rapidly and are now at near-normal levels.  The success we’ve seen recently validates the role our formulations play in our customers’ practices.  Thankfully, we are again seeing trends of record-high revenue days into the third quarter as the economy and healthcare providers continue to make a strong comeback.  Also, we recently announced an important partnership with EyePoint Pharmaceuticals to market FDA-approved DEXYCU, which is the first of hopefully other FDA-approved products we hope to sell through our ImprimisRx platform.  Last, but certainly not least, there are significant catalysts expected over the next few months from Eton, Surface, and Melt that could further value creation for Harrow shareholders.  Please review our Letter to Stockholders for more detail on why we’re excited about the rest of the year.”

Conference Call and Webcast

The company’s management team will host a question and answer conference call with analysts and an audio-only webcast today at 5:00 p.m. Eastern Daylight Time / 2:00 p.m. Pacific Daylight Time.  To participate, please use the dial in or click on the link below:

• U.S. callers: [phone]
• International callers: [phone]
• Audio-only webcast: please click here

Conference Call Replay

A dial in replay of the call will be available until September 10, 2020.  The webcast replay will be available until November 10, 2020.

• U.S. callers: [phone], Replay ID: 35615
• International callers: [phone], Replay ID: 35615
• Webcast: please click here

About Harrow Health

Harrow Health, Inc. (NASDAQ: HROW) owns a portfolio of healthcare businesses, including ImprimisRx, the nation’s leading ophthalmology outsourcing facility and pharmaceutical compounding business. The company holds large equity positions in Eton Pharmaceuticals, Surface Pharmaceuticals, and Melt Pharmaceuticals. Harrow also owns Mayfield Pharmaceuticals, Stowe Pharmaceuticals, and Visionology, all companies founded as subsidiaries of Harrow Health. The Company also owns royalty rights in certain drug candidates being developed by Surface, Melt, and Mayfield. Harrow intends to create, invest in and grow paradigm shifting healthcare businesses that put patients first. For more information about Harrow Health, please visit the Investor Relations section of the corporate website by clicking here.